Scpharmaceuticals Stock Cash And Equivalents
| SCPH Stock | USD 3.28 0.14 4.09% |
Scpharmaceuticals fundamentals help investors to digest information that contributes to Scpharmaceuticals' financial success or failures. It also enables traders to predict the movement of Scpharmaceuticals Stock. The fundamental analysis module provides a way to measure Scpharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Scpharmaceuticals stock.
Scpharmaceuticals | Cash And Equivalents |
Scpharmaceuticals Company Cash And Equivalents Analysis
Scpharmaceuticals' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Scpharmaceuticals Cash And Equivalents | 55.85 M |
Most of Scpharmaceuticals' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Scpharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Scpharmaceuticals Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for Scpharmaceuticals is extremely important. It helps to project a fair market value of Scpharmaceuticals Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since Scpharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Scpharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Scpharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
Scpharmaceuticals Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, Scpharmaceuticals has 55.85 M in Cash And Equivalents. This is 93.2% lower than that of the Pharmaceuticals sector and 87.51% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 97.93% higher than that of the company.
Scpharmaceuticals Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Scpharmaceuticals' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Scpharmaceuticals could also be used in its relative valuation, which is a method of valuing Scpharmaceuticals by comparing valuation metrics of similar companies.Scpharmaceuticals is currently under evaluation in cash and equivalents category among its peers.
Scpharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Scpharmaceuticals from analyzing Scpharmaceuticals' financial statements. These drivers represent accounts that assess Scpharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Scpharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 130.0M | 137.3M | 203.3M | 241.5M | 217.3M | 110.1M | |
| Enterprise Value | 44.9M | 80.7M | 169.6M | 234.9M | 211.4M | 222.0M |
Scpharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Scpharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Scpharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Scpharmaceuticals Fundamentals
| Return On Equity | -1.67 | ||||
| Return On Asset | -0.42 | ||||
| Profit Margin | (2.65) % | ||||
| Operating Margin | (1.81) % | ||||
| Current Valuation | 132.15 M | ||||
| Shares Outstanding | 50.04 M | ||||
| Shares Owned By Insiders | 10.67 % | ||||
| Shares Owned By Institutions | 81.60 % | ||||
| Number Of Shares Shorted | 6.46 M | ||||
| Price To Book | 5.57 X | ||||
| Price To Sales | 5.42 X | ||||
| Revenue | 13.59 M | ||||
| Gross Profit | 21.11 M | ||||
| EBITDA | (46.06 M) | ||||
| Net Income | (54.81 M) | ||||
| Cash And Equivalents | 55.85 M | ||||
| Cash Per Share | 2.04 X | ||||
| Total Debt | 40.27 M | ||||
| Debt To Equity | 0.32 % | ||||
| Current Ratio | 3.72 X | ||||
| Book Value Per Share | 1.03 X | ||||
| Cash Flow From Operations | (59.24 M) | ||||
| Short Ratio | 12.64 X | ||||
| Earnings Per Share | (1.95) X | ||||
| Target Price | 17.5 | ||||
| Number Of Employees | 135 | ||||
| Beta | 0.14 | ||||
| Market Capitalization | 164.13 M | ||||
| Total Asset | 94.48 M | ||||
| Retained Earnings | (281.35 M) | ||||
| Working Capital | 79.8 M | ||||
| Net Asset | 94.48 M |
About Scpharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Scpharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scpharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scpharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Check out Scpharmaceuticals Piotroski F Score and Scpharmaceuticals Altman Z Score analysis. For more detail on how to invest in Scpharmaceuticals Stock please use our How to Invest in Scpharmaceuticals guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Scpharmaceuticals. If investors know Scpharmaceuticals will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Scpharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.95) | Revenue Per Share | Quarterly Revenue Growth 1.641 | Return On Assets | Return On Equity |
The market value of Scpharmaceuticals is measured differently than its book value, which is the value of Scpharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Scpharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Scpharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Scpharmaceuticals' market value can be influenced by many factors that don't directly affect Scpharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Scpharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Scpharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Scpharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.